Skip to content

Theravance Biopharma(Delisted)

US · TBPH #3330 by market cap Listed 2015
0.00 0.00 0.00%
Snapshot may be outdated; check the quote time before use. · 2026-10-22 19:54

Price chart

18.0317.0317.032026-09-232026-09-25
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TBPH?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall A

The radar needs all six factors. Available grades are shown below.

Valuation C+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 16.4x Better than 54%
Forward P/E 6.8x Better than 94%
Price / Sales 8.5x Better than 12%
P/E vs own 5-yr range 85th pctl Better than 21%
Growth C+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 27.9% Better than 89%
Net income CAGR (3Y) -50.5% Better than 4%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -3.4% Better than 18%
Net margin 98.5% Better than 100%
Return on equity 44.8% Better than 93%
Return on invested capital 35.3% Better than 97%
Momentum N/A

Recent price strength, skipping the latest month to avoid short-term noise.

Not enough data to grade this factor.

Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.9x Better than 94%
Debt to assets 8.8% Better than 72%
Interest coverage 53.5x Better than 90%
Free cash flow / net income 225.2% Better than 80%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Key statistics

Price & volume

Prev close
0.00
Open
0.00
Day range
0.00 - 0.00
Avg price
0.00
Volume
0
Turnover
0
Amplitude
0.00%
52-week range
0.00 - 0.00

Valuation

P/E
8.27
P/E (TTM)
16.38
P/B
3.05
EPS
2.06
Net profit
106.95M
Net assets
289.71M

Share structure

Market cap
884.18M
Float cap
440.57M
Shares out
51.92M
Float shares
25.87M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-10-26

Trading activity

Net capital flow main funds, last 45 sessions

-11.12M net over the window

Short interest

Shares short
1.69M
As of
2026-09-15

Frequently asked questions

What is the current stock price of Theravance Biopharma(Delisted) (TBPH)?

Theravance Biopharma(Delisted) last traded at 0.00. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Theravance Biopharma(Delisted)'s market cap?

About 884.18M.

What is the P/E ratio of Theravance Biopharma(Delisted)?

The trailing twelve-month P/E is 16.38, above its own 5-year average of 2.05 — toward the top of its historical range (85.17% percentile). See the Valuation tab for the full history.

Does Theravance Biopharma(Delisted) pay a dividend?

Theravance Biopharma(Delisted) does not currently pay a regular dividend.

What is Theravance Biopharma(Delisted)'s StockVane Quant Rating?

The StockVane Momentum strategy currently rates Theravance Biopharma(Delisted) a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-10-22 19:54:59 · For reference only, not investment advice and not tailored to your situation.

Theravance Biopharma(Delisted) discussion 0 comments

Add a comment